Tag: KZA

Kazia Therapeutics ASX KZA paxalisib drug granted fast track designation treatment glioblastoma brain cancer

Kazia Therapeutics’ paxalisib drug granted fast track designation for treatment of glioblastoma

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has been granted Fast Track Designation by the US Food & Drug Administration for its lead drug paxalisib (formerly G...
Kazia Therapeutics ASX KZA paxalisib drug rare paediatric disease designation FDA

FDA grants Kazia Therapeutics’ paxalisib drug rare paediatric disease designation

Kazia Therapeutics (ASX: KZA) has been awarded Rare Pediatric Disease Designation (RPDD) for its lead drug paxalisib by the FDA for treating Diffuse Intrinsic Pontine Glioma (DIPG). RPDD status mea...
Kazia Therapeutics ASX KZA GBM AGILE glioblastoma brain cancer

Kazia Therapeutics’ lead brain cancer drug selected for international study

Kazia Therapeutics’ (ASX: KZA) lead drug GDC-0084 has been selected for use in GBM AGILE, which is an international academic-led glioblastoma study. According to Kazia, GBM AGILE is an adaptive pha...
Kazia Therapeutics ASX KZA oncology glioblastoma GDC-0084

Kazia Therapeutics reports positive early results from phase 2 glioblastoma trial using GDC-0084

Biotechnology company Kazia Therapeutics (ASX: KZA) has reported early data from a phase 2 study into the effects of lead candidate GDC-0084 on newly-diagnosed brain glioblastomas in adults has shown ...
Kazia Therapeutics ASX KZA Memorial Sloan Kettering Cancer Center radiotherapy clinical trial

Kazia Therapeutics unveils fresh clinical trial for its brain cancer drug candidate

Biotechnology company Kazia Therapeutics (ASX: KZA) has taken a definitive step towards proving the safety and efficacy of its investigational new drug GDC-0084, after announcing a “state of the art” ...
Kazia Therapeutics ASX KZA Glioblastoma brain cancer

Kazia Therapeutics commences clinical trial to redress the balance in glioblastoma treatment options

Glioblastoma is one of the most debilitating and deadly cancers, with limited treatment options that are currently effective for only a third of patients, says Kazia Therapeutics (ASX: KZA) CEO Dr Jam...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS